Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Guided Therapeutics (GTHP) over the last 14 years, with Q3 2025 value amounting to $2.8 million.

  • Guided Therapeutics' Gains from Investment Securities fell 196.4% to $2.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.8 million, marking a year-over-year decrease of 196.4%. This contributed to the annual value of $2.9 million for FY2024, which is 2330.42% up from last year.
  • As of Q3 2025, Guided Therapeutics' Gains from Investment Securities stood at $2.8 million, which was down 196.4% from $3.1 million recorded in Q2 2025.
  • Guided Therapeutics' Gains from Investment Securities' 5-year high stood at $3.1 million during Q2 2025, with a 5-year trough of -$557000.0 in Q4 2021.
  • For the 5-year period, Guided Therapeutics' Gains from Investment Securities averaged around $1.1 million, with its median value being $126000.0 (2021).
  • Its Gains from Investment Securities has fluctuated over the past 5 years, first plummeted by 1520000.0% in 2022, then surged by 23376360.0% in 2023.
  • Quarter analysis of 5 years shows Guided Therapeutics' Gains from Investment Securities stood at -$557000.0 in 2021, then soared by 158.89% to $328000.0 in 2022, then crashed by 85.98% to $46000.0 in 2023, then crashed by 84.78% to $7000.0 in 2024, then soared by 40285.71% to $2.8 million in 2025.
  • Its Gains from Investment Securities was $2.8 million in Q3 2025, compared to $3.1 million in Q2 2025 and -$7000.0 in Q1 2025.